Important role of etiotropic therapy in bacterial intestinal infections in children


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Under the conditions of growing antimicrobial resistance, etiotropic therapy of intestinal infections is one of the most difficult issues of therapy in the practice of a pediatrician, infectious disease specialist, and gastroenterologist. Objective. Evaluation of the safety and efficacy of nifuroxazide in children with acute intestinal infections of various etiologies. Methods. From June 2020 to January 2021, retrospective single-center study with participation of 200 children with acute intestinal infections of various etiologies was conducted at the Pediatric Research and Clinical Center for Infectious Diseases of the FMBA of Russia. The study group included patients who were prescribed the intestinal antiseptic nifuroxazide for therapeutic purposes. The results of the therapeutic use of the drug by the patients were evaluated based on the dynamics of clinical manifestations, as well as changes in the coprograms and the composition of the intestinal microbiota. Results. On the background of the therapy, most patients showed a rapid recovering. The mean length of hospital stay was 4.9 days. Nifuroxazide was used for an average of 4.2 days. Diarrheal syndrome in the study group lasted for 1.8 days. Normalization of temperature in most patients occurred already on the 2nd day from the moment of hospitalization. No serious side effect of the drug nifuroxazide was observed during the entire time period included in the analysis. None of the patients developed antibiotic-associated diarrhea. None of the patients was re-admitted to the Pediatric Research and Clinical Center for Infectious Diseases of the FMBA of Russia during the calendar year after discharge. Conclusion. Thus, the drug nifuroxazide is a safe and effective modern drug that can successfully replace systemic antibiotics in the initial treatment of mild to moderate acute intestinal infections. The study confirms the high safety and good tolerability of nifuroxazide in the treatment of children of all age groups.

Full Text

Restricted Access

About the authors

Konstantin D. Ermolenko

Pediatric Research and Clinical Center for Infectious Diseases of the FMBA

Email: ermolenko.kd@yandex.ru
Cand. Sci. (Med.); Research Department of Intestinal Infections St. Petersburg, Russia

References

  1. Das J.K., Salam R.A., Bhutta Z.A. Global burden of childhood diarrhea and interventions. Curr Opin Inf Dis. 2014;27(5):451-58. doi: 10.1097/QCO.0000000000000096.
  2. Casburn-Jones A.C., Farthing M.J.G. Management of infectious diarrhea. Gut. 2004;53(2):296-305. doi: 10.1136/gut.2003.022103.
  3. Hatchette T.F, Farina D. Infectious diarrhea: when to test and when to treat. CMAJ. 2011;183:339-44. doi: 10.1503/cmaj.091495.
  4. Горелов А.В., Милютина Л.Н., Усенко Д.В. Клинические рекомендации по диагностике и лечению острых кишечных инфекций у детей. Пособие для врачей. М., 2006. 109 с.
  5. Spellberg B., Bartlett J.G., Gilbert D.N. The future of antibiotics and resistance. N Eng J Med. 2012;3-8(4):299-302. doi: 10.1056/NEJMp1215093.
  6. Laxminarayan R. Duse A., Wattal C., et al. Antibiotic resistance - the need for global solutions. Lancet Infect Dis. 2013;13(12):1057-98. doi: 10.1016/S1473-3099(13)70318-9.
  7. Wong M.H.Y, et al. Emergence of Clinical Salmonella enterica Serovar Typhimurium Isolates with Concurrent Resistance to Ciprofloxacin, Ceftriaxone, and Azithromycin. Antimicrob Agent Chemother. 2014;58(7):3752-56. doi: 10.1128/AAC.02770-13.
  8. Ganguly N.K., Arora N.K., Chandy S.J., et al, for the Global Antibiotic Resistance Partnership (GARP)-India Working Group. Rationalizing antibiotic use to limit antibiotic resistance in India. Ind J Med Res. 2011;134:281-94.
  9. Геппе Н.А., Горелов А.В., Дронов И.А. Проблемы антибактериальной терапии при кишечных инфекциях у детей. Медицинский совет. 2011;5:22-6.
  10. Горелов А.В., Николаева С.В., Усенко Д.В. и др. Эффективность применения нифуроксазида при острых кишечных инфекциях бактериальной этиологии у детей. Инфекционные болезни. 8-16Д6(o):18-26. doi: 10.40953/1749-9445-4018-4-18-46.
  11. Руженцова Т.А. и др. Нифуроксазид в терапии острых кишечных инфекции у детей: результаты мета-анализа. Инфекционные болезни. 4040;18(2):88-36.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies